Your browser is no longer supported. Please, upgrade your browser.
Settings
SGEN [NASD]
Seagen Inc.
Index- P/E- EPS (ttm)-1.85 Insider Own0.60% Shs Outstand182.30M Perf Week-11.07%
Market Cap29.01B Forward P/E- EPS next Y-0.87 Insider Trans-40.54% Shs Float181.66M Perf Month-19.27%
Income-332.70M PEG- EPS next Q-0.26 Inst Own91.70% Short Float1.79% Perf Quarter-0.97%
Sales1.75B P/S16.62 EPS this Y451.20% Inst Trans1.82% Short Ratio3.94 Perf Half Y-2.12%
Book/sh17.36 P/B8.68 EPS next Y110.00% ROA-8.40% Target Price192.28 Perf Year-16.33%
Cash/sh12.66 P/C11.91 EPS next 5Y39.20% ROE-9.90% 52W Range133.20 - 202.60 Perf YTD-13.93%
Dividend- P/FCF- EPS past 5Y41.20% ROI17.10% 52W High-25.60% Beta0.79
Dividend %- Quick Ratio4.20 Sales past 5Y45.20% Gross Margin83.60% 52W Low13.17% ATR6.55
Employees2092 Current Ratio4.50 Sales Q/Q-60.10% Oper. Margin-19.80% RSI (14)23.13 Volatility4.41% 3.61%
OptionableYes Debt/Eq0.00 EPS Q/Q-146.10% Profit Margin-19.10% Rel Volume1.75 Prev Close158.67
ShortableYes LT Debt/Eq0.00 EarningsOct 28 AMC Payout- Avg Volume826.01K Price150.74
Recom2.10 SMA20-14.95% SMA50-13.08% SMA200-3.70% Volume1,444,814 Change-5.00%
Nov-09-21Initiated Wolfe Research Peer Perform $195
Oct-15-21Resumed BTIG Research Neutral
May-17-21Initiated Evercore ISI In-line
Mar-31-21Initiated Credit Suisse Neutral $145
Feb-01-21Downgrade RBC Capital Mkts Outperform → Sector Perform $188 → $186
Jan-15-21Upgrade BofA Securities Neutral → Buy $215
Sep-22-20Reiterated Stifel Hold $145 → $165
Aug-24-20Resumed Berenberg Buy $187
Jul-31-20Reiterated H.C. Wainwright Buy $175 → $200
Jul-24-20Downgrade Piper Sandler Overweight → Neutral
May-26-20Initiated JMP Securities Mkt Outperform $185
May-01-20Upgrade Guggenheim Neutral → Buy
May-01-20Reiterated Needham Buy $157 → $163
Feb-18-20Downgrade Barclays Overweight → Equal Weight $124
Feb-12-20Reiterated H.C. Wainwright Buy $140 → $150
Feb-11-20Reiterated Goldman Buy $126 → $165
Jan-28-20Initiated BMO Capital Markets Outperform
Jan-27-20Initiated BMO Capital Markets Outperform
Jan-02-20Downgrade Guggenheim Buy → Neutral
Dec-10-19Initiated Morgan Stanley Equal-Weight
Nov-19-21 09:33AM  
Nov-15-21 10:44AM  
Nov-09-21 08:54AM  
Nov-04-21 09:31AM  
Oct-29-21 07:01AM  
Oct-28-21 05:45PM  
04:02PM  
Oct-21-21 03:03PM  
Oct-19-21 01:09PM  
Oct-12-21 09:35AM  
08:00AM  
08:00AM  
Oct-07-21 08:00AM  
Sep-28-21 08:00AM  
Sep-27-21 03:00AM  
03:00AM  
Sep-20-21 05:05PM  
05:03PM  
05:00PM  
Sep-19-21 11:30AM  
Sep-13-21 11:18AM  
Sep-09-21 08:00AM  
Sep-08-21 08:00AM  
Aug-17-21 01:15PM  
Aug-09-21 06:00AM  
Jul-30-21 10:03AM  
Jul-29-21 05:25PM  
04:02PM  
Jul-22-21 03:03PM  
Jul-09-21 02:10PM  
02:10PM  
Jul-08-21 08:00AM  
Jun-28-21 09:43AM  
Jun-16-21 06:38AM  
Jun-03-21 06:00AM  
Jun-02-21 08:00AM  
May-25-21 01:12PM  
May-19-21 05:00PM  
05:00PM  
Apr-30-21 03:01AM  
Apr-29-21 05:25PM  
04:02PM  
02:30PM  
08:00AM  
Apr-22-21 12:33PM  
Apr-19-21 08:00AM  
08:00AM  
Apr-16-21 07:07AM  
Apr-09-21 04:00PM  
04:00PM  
08:00AM  
Apr-07-21 08:00AM  
Mar-26-21 02:00AM  
Mar-18-21 06:02PM  
Mar-13-21 10:30AM  
Mar-05-21 08:00AM  
Feb-27-21 09:23AM  
Feb-24-21 08:00AM  
Feb-18-21 08:00AM  
08:00AM  
Feb-15-21 05:41AM  
Feb-12-21 02:15PM  
02:15PM  
02:15PM  
02:15PM  
10:28AM  
06:45AM  
05:31AM  
Feb-11-21 05:45PM  
04:02PM  
02:30PM  
Feb-10-21 04:05PM  
Jan-07-21 08:00AM  
Dec-30-20 12:04PM  
Dec-16-20 08:00AM  
03:18AM  
Dec-11-20 07:23AM  
Dec-08-20 08:00AM  
Dec-07-20 10:00AM  
Nov-11-20 03:15AM  
Nov-09-20 08:00AM  
Nov-05-20 08:00AM  
Nov-03-20 08:57AM  
06:17AM  
Nov-02-20 08:00AM  
Oct-30-20 01:07PM  
06:01AM  
Oct-29-20 06:05PM  
04:02PM  
Oct-28-20 08:00AM  
Oct-22-20 12:33PM  
12:27PM  
Oct-13-20 01:33PM  
08:00AM  
Oct-12-20 06:45AM  
06:45AM  
Oct-08-20 08:00AM  
Oct-07-20 09:44AM  
Oct-05-20 11:13AM  
Oct-03-20 06:55AM  
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and SpringWorks Therapeutics, Inc. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAKER BROS. ADVISORS LPDirectorDec 01Sale161.2193,45115,064,9404,069,762Dec 02 06:51 PM
BAKER BROS. ADVISORS LPDirectorNov 30Sale160.33301,44448,331,4514,077,649Dec 02 06:51 PM
HIMES VAUGHN BChief Technical OfficerNov 11Option Exercise26.106,000156,60065,845Nov 12 06:51 PM
HIMES VAUGHN BChief Technical OfficerNov 11Sale178.636,0001,071,77459,845Nov 12 06:51 PM
SIMPSON TODD EChief Financial OfficerNov 04Option Exercise46.372,15699,974128,803Nov 05 05:21 PM
LIU JEAN IGC/EVP, Leg AffairsNov 04Option Exercise46.371,61774,98070,708Nov 05 05:21 PM
SIMPSON TODD EChief Financial OfficerNov 03Option Exercise44.0940,2321,773,829166,879Nov 05 05:21 PM
SIMPSON TODD EChief Financial OfficerNov 03Sale185.0040,2327,442,920126,647Nov 05 05:21 PM
LIU JEAN IGC/EVP, Leg AfairsNov 01Option Exercise35.9534,8761,253,792103,967Nov 03 09:18 PM
HIMES VAUGHN BChief Technical OfficerNov 01Option Exercise46.372,15699,97459,845Nov 03 07:20 PM
LIU JEAN IGC/EVP, Leg AfairsNov 01Sale177.4134,8766,187,36969,091Nov 03 09:18 PM
SIMPSON TODD EChief Financial OfficerOct 29Option Exercise41.0433,5641,377,467160,211Nov 02 06:46 PM
SIMPSON TODD EChief Financial OfficerOct 29Sale180.0033,5646,041,523126,647Nov 02 06:46 PM
HIMES VAUGHN BChief Technical OfficerSep 08Option Exercise26.106,000156,60063,488Sep 10 07:22 PM
HIMES VAUGHN BChief Technical OfficerSep 08Sale150.006,000900,00057,488Sep 10 07:22 PM
SIEGALL CLAY BPresident and CEOAug 31Sale169.9210,4321,772,575682,809Aug 31 09:28 PM
DANSEY ROGER DChief Medical OfficerAug 31Sale167.524,611772,41485,339Sep 02 08:07 PM
SIEGALL CLAY BPresident & CEOAug 31Sale167.5214,3512,404,015668,458Sep 02 07:59 PM
LIU JEAN IGC/EVP, Legal AffairsAug 31Sale167.523,648611,09768,931Sep 02 07:58 PM
SIMPSON TODD EChief Financial OfficerAug 31Sale167.523,987667,884126,446Sep 02 07:57 PM
HIMES VAUGHN BChief Technical OfficerAug 31Sale167.523,584600,37657,488Sep 02 07:53 PM
ROMP CHARLES REVP, CommercialAug 31Sale167.521,133189,79551,184Sep 02 07:49 PM
SIEGALL CLAY BPresident and CEOAug 30Sale166.8635,7065,957,816693,241Aug 31 09:28 PM
SIEGALL CLAY BPresident and CEOAug 27Sale169.0514,2942,416,390728,947Aug 31 09:28 PM
ROMP CHARLES REVP, CommercialAug 16Sale154.55777120,08842,410Aug 18 08:29 PM
HIMES VAUGHN BChief Technical OfficerAug 16Sale154.55658101,69752,354Aug 18 08:29 PM
SIEGALL CLAY BPresident & CEOAug 16Sale154.552,789431,051712,420Aug 18 08:29 PM
SIMPSON TODD EChief Financial OfficerAug 16Sale154.5553382,377119,338Aug 18 08:28 PM
LIU JEAN IGC/EVP, Leg AffairsAug 16Sale154.55718110,97063,333Aug 18 08:28 PM
DANSEY ROGER DChief Medical OfficerAug 16Sale154.551,657256,09672,778Aug 18 08:28 PM
DANSEY ROGER DChief Medical OfficerAug 13Sale156.5910,0001,565,86774,435Aug 13 09:39 PM
SIEGALL CLAY BPresident & CEOAug 06Option Exercise15.465,79389,560718,885Aug 06 08:28 PM
SIEGALL CLAY BPresident & CEOAug 06Sale159.705,793925,134715,209Aug 06 08:28 PM
SIEGALL CLAY BPresident & CEOAug 05Option Exercise15.4623,560364,238724,471Aug 06 08:28 PM
SIEGALL CLAY BPresident & CEOAug 05Sale163.0823,5603,842,086715,209Aug 06 08:28 PM
SIEGALL CLAY BPresident and CEOJul 02Option Exercise15.4615,268236,043722,621Jul 06 09:40 PM
ROMP CHARLES REVP, CommercialJul 02Sale158.41703111,36243,187Jul 06 08:13 PM
SIEGALL CLAY BPresident and CEOJul 02Sale156.3615,2682,387,233715,209Jul 06 09:40 PM
SIEGALL CLAY BPresident and CEOJul 01Option Exercise15.4614,085217,754721,374Jul 06 09:40 PM
SIEGALL CLAY BPresident and CEOJul 01Sale157.7814,0852,222,376715,209Jul 06 09:40 PM
DANSEY ROGER DChief Medical OfficerJun 16Sale152.2225,1093,822,03484,435Jun 21 06:02 PM
HIMES VAUGHN BChief Technical OfficerJun 07Option Exercise26.101,30334,00854,315Jun 08 08:50 PM
HIMES VAUGHN BChief Technical OfficerJun 07Sale150.001,303195,45053,012Jun 08 08:50 PM
HIMES VAUGHN BChief Technical OfficerJun 03Option Exercise15.4610,697165,37663,709Jun 04 08:21 PM
SIEGALL CLAY BPresident and CEOJun 03Option Exercise15.4629,353453,797723,884Jun 04 08:22 PM
SIEGALL CLAY BPresident and CEOJun 03Sale144.5129,3534,241,801715,209Jun 04 08:22 PM
HIMES VAUGHN BChief Technical OfficerJun 03Sale144.9110,6971,550,09053,012Jun 04 08:21 PM
ROMP CHARLES REVP, CommercialMay 17Sale145.9533448,74643,890May 19 07:10 PM
BAKER BROS. ADVISORS LPDirectorMay 14Option Exercise19.0235,000665,70043,307,671May 18 04:23 PM
LIU JEAN IGC/EVP, Leg AffairsMay 11Sale140.001,061148,54064,051May 13 07:17 PM
SIEGALL CLAY BPresident and CEOMay 06Option Exercise15.4629,353453,797733,288May 07 06:29 PM
SIEGALL CLAY BPresident and CEOMay 06Sale134.9729,3533,961,824715,209May 07 06:29 PM
SIEGALL CLAY BPresident and CEOApr 09Option Exercise15.4612,602194,827721,310Apr 09 08:13 PM
SIEGALL CLAY BPresident and CEOApr 09Sale141.9612,6021,788,924715,209Apr 09 08:13 PM
SIEGALL CLAY BPresident and CEOApr 08Option Exercise15.4616,751258,970724,376Apr 09 08:13 PM
SIEGALL CLAY BPresident and CEOApr 08Sale145.1716,7512,431,816715,209Apr 09 08:13 PM
SIEGALL CLAY BPresident and CEOMar 04Option Exercise15.4629,353453,797726,618Mar 05 07:56 PM
SIEGALL CLAY BPresident and CEOMar 04Sale145.7429,3534,277,763715,209Mar 05 07:56 PM
HIMES VAUGHN BChief Technical OfficerMar 02Option Exercise15.4612,000185,520141,889Mar 04 07:27 PM
HIMES VAUGHN BChief Technical OfficerMar 02Sale153.2212,0001,838,623129,889Mar 04 07:27 PM
LIU JEAN IGC/EVP, Leg AffairsFeb 17Option Exercise41.374,846200,46665,112Feb 18 08:48 PM
SIEGALL CLAY BPresident and CEOFeb 04Option Exercise15.4629,353453,797726,706Feb 05 08:00 PM
SIEGALL CLAY BPresident and CEOFeb 04Sale165.5729,3534,860,105715,209Feb 05 08:00 PM
LIU JEAN IGC/EVP, Leg AffairsJan 15Option Exercise35.955,000179,75065,266Jan 15 07:40 PM
LIU JEAN IGC/EVP, Leg AffairsJan 15Sale180.005,000900,00060,266Jan 15 07:40 PM
SIEGALL CLAY BPresident and CEOJan 07Option Exercise15.4629,353453,797719,687Jan 08 07:52 PM
SIEGALL CLAY BPresident and CEOJan 07Sale172.4429,3535,061,681715,209Jan 08 07:52 PM
SIMPSON TODD EChief Financial OfficerDec 18Option Exercise26.7134,773928,772152,436Dec 18 08:51 PM
SIMPSON TODD EChief Financial OfficerDec 18Sale200.0033,6696,733,800118,767Dec 18 08:51 PM
LIU JEAN IGC/EVP, Leg AffairsDec 16Option Exercise35.951,62458,38360,266Dec 16 07:41 PM
LIU JEAN IGC/EVP, Leg AffairsDec 14Option Exercise35.955,000179,75063,642Dec 16 07:41 PM
LIU JEAN IGC/EVP, Leg AffairsDec 14Sale195.865,000979,31658,642Dec 16 07:41 PM
SIEGALL CLAY BPresident and CEODec 07Option Exercise15.4615,723243,078720,265Dec 08 07:33 PM
HIMES VAUGHN BChief Technical OfficerDec 07Option Exercise25.3612,761323,646199,590Dec 09 08:08 PM
HIMES VAUGHN BChief Technical OfficerDec 07Sale181.768,0001,454,041191,590Dec 09 08:08 PM
SIEGALL CLAY BPresident and CEODec 07Sale181.1415,7232,848,122715,209Dec 08 07:33 PM